Physician profile
Candice White
NPI 1104272079
$2,483.57
in general payments reported to CMS, 2019-2025
13 companies · $471 in 2025
The $471 reported for 2025 was more than what 76% of Critical Care Medicine (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $203).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $163 · 2024: $1,551 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,060 · Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,059.52 |
| Food and Beverage | $961.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,258.96 | 2024-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $376.08 | 2021-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.85 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $124.57 | 2025 | Opsumit, Uptravi |
| Astellas Pharma US INC | $100.00 | 2022 | |
| United Therapeutics Corporation | $69.28 | 2024 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $49.68 | 2021-2024 | Wainua |
| Merck Sharp & Dohme LLC | $35.41 | 2021-2024 | Verquvo |
| Medtronic, INC. | $23.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.92 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $20.52 | 2024 | Amvuttra |
| Daiichi Sankyo INC. | $17.52 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.